Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target

被引：113

作者：

Krystof, Vladimir ^{[1
,2
]}

Baumli, Sonja ^{[3
]}

Fuerst, Robert ^{[4
]}

机构：

[1] Palacky Univ, Lab Growth Regulators, Fac Sci, Olomouc 78371, Czech Republic

[2] Inst Expt Bot ASCR, Olomouc 78371, Czech Republic

[3] Univ Newcastle, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England

[4] Univ Munich, Dept Pharm, Ctr Drug Res Pharmaceut Biol, D-81377 Munich, Germany

来源：

CURRENT PHARMACEUTICAL DESIGN | 2012年 / 18卷 / 20期

基金：

英国医学研究理事会;

关键词：

Cancer; inflammation; kinase; P-TEFb; inhibitor; therapeutics; angiogenesis; FLAVOPIRIDOL INDUCES APOPTOSIS; GROWTH-FACTOR EXPRESSION; MULTIPLE-MYELOMA CELLS; P-TEFB; TRANSCRIPTION ELONGATION; KAPPA-B; DOWN-REGULATION; CDK9/CYCLIN T1; SELICICLIB CYC202; CRYSTAL-STRUCTURE;

D O I：

10.2174/138161212800672750

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.

引用

页码：2883 / 2890

页数：8

共 50 条

[1] Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
Ma, Hangzhan
Seebacher, Nicole A.
Hornicek, Francis J.
Duan, Zhenfeng
EBIOMEDICINE, 2019, 39 : 182 - 193
[2] Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer
Wang, Jinglu
Dean, Dylan C.
Hornicek, Francis J.
Shi, Huirong
Duan, Zhenfeng
FASEB JOURNAL, 2019, 33 (05): : 5990 - 6000
[3] Cyclin-dependent kinase 9 (CDK9) as a therapeutic target in uveal and triple-wild type melanoma
Shaughnessy, M.
La Muraglia, G.
Rajadurai, A.
Kumar, R.
Olson, C.
Jiang, B.
Gray, N.
Tsao, H.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S121 - S121
[4] Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma
Walker, Robert L.
Hornicek, Francis J.
Duan, Zhenfeng
BIOCHEMICAL PHARMACOLOGY, 2024, 226
[5] Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo
Majello, B
Napolitano, G
Giordano, A
Lania, L
ONCOGENE, 1999, 18 (32) : 4598 - 4605
[6] Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo
Barbara Majello
Giuliana Napolitano
Antonio Giordano
Luigi Lania
Oncogene, 1999, 18 : 4598 - 4605
[7] Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
Parvathareddy, Sandeep Kumar
Siraj, Abdul K.
Masoodi, Tariq
Annaiyappanaidu, Padmanaban
Al-Badawi, Ismail A.
Al-Dayel, Fouad
Al-Kuraya, Khawla S.
JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
[8] Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer
Sandeep Kumar Parvathareddy
Abdul K. Siraj
Tariq Masoodi
Padmanaban Annaiyappanaidu
Ismail A. Al-Badawi
Fouad Al-Dayel
Khawla S. Al-Kuraya
Journal of Ovarian Research, 14
[9] Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity
Xu, Junyu
Li, Hongmei
Wang, Xinren
Huang, Jianhang
Li, Shuwen
Liu, Chenhe
Dong, Ruinan
Zhu, Gaoyuan
Duan, Chunqi
Jiang, Fei
Zhang, Yanmin
Zhu, Yuqin
Zhang, Tianyi
Chen, Yadong
Tang, Weifang
Lu, Tao
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 200
[10] Functional interaction between Tax and the cyclin dependent kinase CDK9
Lu, H
Zhou, M
Park, H
Brady, J
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (05) : 491 - 491

← 1 2 3 4 5 →